| Medication | Response | Ε | |
| + | – | ||
| A (raltegravir) | 293 (84.4%) | 54 (15.6%) | 347 (100.0%) |
| B (lopinavir + ritonavir) | 319 (90.6%) | 33 (9.4%) | 352 (100.0%) |
| Ε | 612 | 87 | 699 |
Setting the non-inferiority margin at 0.5 and using SASTM software (for details see [4, section 6.6.1]), the p value Psε for this contingency table comes out as 35.04%, far above the usual significance level of 5%. Thus, non-inferiority of raltegravir to the combination therapy with regard to the odds ratio cannot be confirmed on the basis of these data.